Home Blog Page 2431

Volvo Trucks: Advancing Road Safety Across Southeast Asia

By
Advertorial Desk
-

Collaboration with Schools and Communities to Protect Children and Vulnerable Road Users

In the compact and dynamic city-state of most countries in Southeast Asia, ensuring road safety is one of the nation’s top priorities. But there is always room for improvement, and keeping safety front and centre on the agenda will not only save lives but maintain economic strength says Anna Engblom, Managing Director – Southeast Asia and Japan at Volvo Trucks.

SINGAPORE, Sept. 30, 2025 /PRNewswire/ — Volvo Trucks, a global leader in commercial vehicle safety, is amplifying its commitment to road safety across Southeast Asia, where over 120,000 road accident fatalities occur each year – nearly 15% of road deaths worldwide. The most vulnerable groups are children, pedestrians, and motorcyclists. In response, governments in Malaysia, Thailand, Indonesia, Singapore, and the Philippines have introduced dedicated road safety months. These initiatives combine educational seminars, community outreach, and stricter enforcement, contributing to a 5-10% reduction in road-related injuries during campaign periods.

The ‘Stop, Look, Wave’ activity at Brunei
The ‘Stop, Look, Wave’ activity at Brunei

Central to Volvo’s advocacy are two flagship programs. The ‘Stop, Look, Wave’ campaign, run in collaboration with schools, teaches children to pause at the curb, look both ways, and wave to drivers before crossing. In 2024-2025 alone, over 30,000 children took part in interactive workshops, leading to a measurable increase in safe crossing behaviors. The ‘See and Be Seen’ initiative educates both children and adults about truck blind spots and the importance of ensuring visibility around large vehicles, helping all road users better understand risks and safe conduct. Our most recent campaigns have been at Japan and Brunei, demonstrating the brand’s regional dedication to protecting lives and fostering a culture of safety for all road users.

Ms. Anna Engblom, Managing Director, Volvo Trucks Southeast Asia & Japan said, “At Volvo Trucks, people are at the core of our safety commitment. Our responsibility extends beyond drivers to everyone sharing the road. We believe safety is achieved not only through advanced technology but also through community education and awareness. Our pursuit of zero accidents guides our innovations and partnerships, fostering a culture where every road user’s well-being is prioritized, and ultimately creating safer, more secure roads for all.”

Volvo Trucks’ vision is zero accidents involving its vehicles. Acknowledging that over a million lives are lost globally to road accidents each year, Volvo believes true progress comes from a holistic approach: prioritizing safety for those inside and outside the truck. This drives the company to go beyond legal requirements, investing in advanced technology, education, and close community partnerships. While innovations in vehicle design are crucial, Volvo emphasizes that the primary safety system is the driver’s awareness and training.

If you are interested in joining us or would like to collaborate on a campaign at your school or class, please feel free to reach out to our team or your local market representatives.

Protecting lives & fostering a culture of safety for all road users
Protecting lives & fostering a culture of safety for all road users

Ms. Anna Engblom, Managing Director, Volvo Trucks Southeast Asia & Japan
Ms. Anna Engblom, Managing Director, Volvo Trucks Southeast Asia & Japan

Novartis Singapore and the Singapore Heart Foundation Launch ‘Beat the Block’ Campaign to Raise Awareness of High Blood Cholesterol

By
Advertorial Desk
-
  • Local survey reveals critical misconceptions and gaps in blood cholesterol management among people living in Singapore.
  • Almost one in three deaths in Singapore is attributed to cardiovascular disease, underscoring the urgent need to improve blood cholesterol management.[1]
  • Beat the Block was launched to raise awareness of optimal low-density lipoprotein cholesterol (LDL-C) levels, a critical starting point in managing heart health.

SINGAPORE, Sept. 30, 2025 /PRNewswire/ — Novartis Singapore (Novartis) and the Singapore Heart Foundation (SHF) have jointly launched Beat the Block — a blood cholesterol management education campaign. Designed to address critical knowledge gaps identified in a joint survey, the campaign offers science-based information and practical tools to help people in Singapore manage their heart health.

While the prevalence of high blood cholesterol (hypercholesterolemia) among people living in Singapore has decreased from 39.1% in 2020 to 31.9% in 2022, cardiovascular disease (CVD) remains the top killer in the country, accounting for approximately one in three deaths. [2] The survey commissioned by Novartis and SHF and conducted by IQVIA revealed widespread blood cholesterol management misconceptions, underscoring the urgent need for increased awareness and proactive management of low-density lipoprotein cholesterol (LDL-C) levels to prevent CVD-related deaths.

Talking about the urgency of this campaign, Mr. Geoffrey Ong, Chief Executive Officer, Singapore Heart Foundation said: “As the Singapore Heart Foundation marks its 55th anniversary in 2025, this campaign serves as a timely reminder of our mission to build resilient hearts for a healthier Singapore. Heart health is not merely a medical concern — it is fundamental to the strength and vitality of individuals, families, and communities. By spotlighting the importance of blood cholesterol management, we reinforce the prevention of cardiovascular disease and help reduce preventable disability and premature death. Misconceptions that downplay its significance can lead to inaction and serious health consequences. It is essential to educate the public on the importance of effectively managing blood cholesterol to prevent long-term health issues and potentially even loss of life.”

Addressing Misconceptions in Blood Cholesterol Management
The survey painted a concerning picture. Approximately 80% of cardiovascular disease is preventable, including heart disease and stroke,[3] and the link between high blood cholesterol and cardiovascular disease is well understood — yet only 36% of respondents strongly agree that high blood cholesterol requires urgent attention.[4]

While a healthy lifestyle forms the bedrock of good health, it alone may not be sufficient to manage blood cholesterol. In some cases, cholesterol-lowering medication is necessary, but people living in Singapore are hesitant about these treatments. In fact, the survey revealed several common misconceptions: 93% of respondents think that diet and exercise are equally as effective in lowering blood cholesterol as prescription medication; 72% believe the long-term use of statins can damage the kidneys and liver; and 60% fear that the long-term use of statins could lead to a higher risk of cancer.[4]

The survey also found that, among respondents diagnosed with high blood cholesterol, approximately three in 10 do not take medication, with the most common reason being fear of safety and side effects.[4] Among patients who were taking medication, 37% of respondents report being non-compliant with their prescriptions. When asked why, the top responses were the belief that their blood cholesterol levels were already under control, feeling fine despite missing doses, concerns about long-term side effects as well as already taking too many pills to manage other health conditions. [4] These indicate a significant gap in understanding the ongoing need for proactive blood cholesterol management and timely intervention.

The consequences of neglecting blood cholesterol management can be severe, including an increased risk of cardiovascular events. Alarmingly, less than one-third of all respondents know their total blood cholesterol levels or the optimal range.[4]

Dr. Bernard Kwok, an accomplished cardiologist and Immediate-Past Honorary Treasurer of the Singapore Heart Foundation’s Board of Directors, shares: “High blood cholesterol is silent and has no symptom. It can impact anyone, regardless of gender, ethnicity, or perceived fitness levels. It is crucial for all adults to regularly check their blood cholesterol levels and consult their doctors to manage heart health.” Dr. Kwok is also Past-President of the Singapore Cardiac Society and founding President of the Heart Failure Society (Singapore).

Introducing the Cardiovascular Risk Calculator
One of the key tools offered through the Beat the Block campaign is the Cardiovascular Risk Calculator. It is built on the recalibrated Singapore-modified Framingham Risk Score (SG-FRS-2023) and estimates an individual’s 10-year risk of developing coronary artery disease (CAD). The calculation is based on inputs such as age, sex, race, total and HDL cholesterol, systolic blood pressure, use of blood pressure medication, diabetes status and smoking status. In addition to risk estimation, the calculator also provides a recommended LDL-C target tailored to the user’s profile.

LDL-C is a critical parameter in managing blood cholesterol. Often referred to as “bad” cholesterol, high levels of LDL-C can lead to the buildup of plaques in arteries, increasing the risk of CVD. Understanding and managing LDL-C levels is essential for preventing heart attacks and strokes.

“Beat the Block addresses the misconception that health maintenance is only necessary for diseases with obvious or immediate effects. By spotlighting facts and serving periodic reminders, we encourage individuals to recognise the importance of proactive blood cholesterol management, even when the consequences are not immediately visible. Effective management includes not only lifestyle changes but also adherence to prescribed medications, crucial for controlling blood cholesterol levels and preventing complications. The Singapore Heart Foundation’s mission is to champion heart health, and to alleviate the impact of cardiovascular disease and stroke. Our collaboration with Singapore Heart Foundation through this campaign aims to achieve that.” says Ms. Poh Hwee Tee, Country President of Novartis Singapore and Asian Emerging Markets.

The online survey engaged 1,000 Singapore citizens and permanent residents, evenly split between patients and caregivers diagnosed with hypercholesterolemia and those who have not been diagnosed with hypercholesterolemia. Respondents were between the age range of 21 to 75, with balanced representation of both genders and fair distribution of patients receiving treatment across public and private settings.

To learn more about the Beat the Block campaign and access the Cardiovascular Risk Calculator, please visit: http://beattheblock.sg.

Note: The fieldwork for the survey was conducted between April and June 2023.

References 

  1. Singapore Heart Foundation. Heart Disease Statistics. Available at: https://www.myheart.org.sg/health/heart-disease-statistics/  [Last accessed: September 8, 2025]
  2. Singapore Heart Foundation. High Blood Cholesterol. Available at: https://www.myheart.org.sg/health/risk-factors/high-blood-cholesterol/ [Last accessed: September 8, 2025]
  3. World Heart Foundation. Prevention. Available at: https://world-heart-federation.org/what-we-do/prevention/. [Last accessed: September 8, 2025].
  4. Actual results of a survey titled ‘The knowledge, attitudes, beliefs and behaviour of Singaporeans towards cholesterol management’ commissioned by Singapore Heart Foundation and Novartis and conducted by IQVIA in 2023 – data on file.

 

About the “Beat the Block” Campaign
Beat the Block is a blood cholesterol management education campaign jointly led by Novartis Singapore and the Singapore Heart Foundation. It is designed to provide holistic, science-backed information and actionable tools to help people living in Singapore care for their hearts, starting with knowing their blood cholesterol numbers.

About Novartis 
Novartis is an innovative medicines company. Every day, we work to reimagine medicine to improve and extend people’s lives so that patients, healthcare professionals and societies are empowered in the face of serious disease. Our medicines reach nearly 300 million people worldwide.

Reimagine medicine with us: Visit us at https://www.novartis.com and connect with us on LinkedIn.

About Singapore Heart Foundation
The Singapore Heart Foundation (SHF) is a social service agency at the forefront of the battle against heart disease since 1970. Driven by an unwavering vision of a healthier Singapore population, SHF is dedicated to promoting better heart health for every individual living in Singapore, through evidence-based information and practices that keep every heart beating healthily.

Through strategic life-saving initiatives underlined by the three core pillars of Prevention, Rehabilitation and Resuscitation, SHF upholds its enduring mission to champion heart health and to alleviate the impact of cardiovascular disease and stroke. It aims to prevent not only physical suffering but also the premature loss of precious lives.

With three Heart Wellness Centres (HWC) located across the island, heart patients and those at risk can enrol in a highly subsidised, structured community-based cardiac rehabilitation programme, priced at just $5 per session. SHF also extends a helping hand to those in need by providing financial assistance to heart patients in the moments of crisis and ensuring that they receive the timely support and medical care that they require.

Community First Responders (CFRs), trained in cardiopulmonary resuscitation (CPR) and the use of automated external defibrillators (AED), play a pivotal role in SHF’s mission to better heart health. SHF also provides CPR and AED courses to train more CFRs with the objective of building a nation of lifesavers. The Foundation also plays an integral role in ensuring the accessibility and serviceability of AEDs islandwide.

 

Johnson & Johnson Launches “Dual Control” Campaign in Asia Pacific to Empower Patients with IBD to Balance Disease Management and Dreams

By
Advertorial Desk
-

New IBD research shows that, even during clinical remission, people living with Crohn’s disease continue to experience greater work impairment than the general population

The new campaign aims to empower patients to take dual control of disease management and life aspirations by striving for endoscopic remission through shared decision-making

SINGAPORE, Sept. 30, 2025 /PRNewswire/ — Johnson & Johnson today launched the Dual Control campaign in Asia Pacific to raise awareness about the importance of enhanced shared decision-making and how it can help patients achieve sustained endoscopic remission, enabling patients with inflammatory bowel disease (IBD) to take dual control of the condition and their life aspirations. The campaign provides a range of educational resources across Asia Pacific.

Crohn’s disease (CD) and ulcerative colitis (UC), the two main forms of IBD, affect around 10 million people worldwide, and the number of patients is increasing in Asia[1],[2],[3]. Typically beginning in adolescence[4], IBD causes symptoms like diarrhea, blood in stool, and abdominal pain[5], affecting schooling[6], careers[7], and relationship development[8]—forcing many to live a ‘double life’—appearing normal while silently struggling with the condition.

Globally, only 10% of CD patients experience sustained clinical remission[9], and many UC patients still rely on traditional treatments[10]. Recent findings from a sub-analysis of iCREST-CD study in Japan, the largest nation-wide cohort study in Asia for newly diagnosed patients with CD, revealed that presenteeism—impairment while working—remains higher at 25.7% among patients with CD who were in clinical remission, compared to 20.1% in the general Japanese population[11],[12]. This indicates the need for disease management that can help provide sustained and deeper remission.

Although IBD treatments have advanced, less than 40% of patients had previously heard of the term “mucosal healing” (endoscopic remission), which refers to the absence of active disease seen during a colonoscopy, compared to clinical remission which focuses on symptom resolution[13],[14].

Dr. Kenji Watanabe, Professor, Department of Internal Medicine for IBD at University of Toyama, Japan, emphasized: “The disconnect on treatment goals highlights the need for shared decision making to help elevate IBD care. A trusted relationship and open communication between patients and clinicians are essential to bridge this knowledge gap, equip patients for discussions on treatment preferences, and help them pursue their aspirations and live fully.”

There has been an identified discrepancy regarding the definition of remission between patients and physicians, which could affect treatment expectations and outcomes[13]. Patients often define remission as symptom resolution, while physicians rely on test results like colonoscopy or sigmoidoscopy[14]. Endoscopic remission correlates with a better quality of life, lower risks of surgery and hospitalization[15], and a higher likelihood of sustained remission[16].

“Living with IBD is overwhelming for many patients,” said Ms. Nidhi Swarup, President of the Crohn’s & Colitis Society of Singapore and a patient living with CD for more than 10 years. “We are eager to understand more about our condition and available treatment options. We need holistic care which includes easy-to-digest educational materials, affordable treatment options, peer support and compassionate care from the medical team to achieve this. When patients have access to clear information and feel supported, we can actively participate in our care and work towards our personal goals.”

Shared decision making could help patients and doctors partner more effectively to improve treatment outcomes[17], but it remains underutilized across Asia. While more than 80% of IBD patients and physicians favor shared decision making globally[17], 53% of patients in Japan worry about asking too many questions[18], and 30% of patients in China express dissatisfaction with the depth and length of dialogue at consultations[19].

Dr. Yan Chen, Co-Founder of the China Crohn’s and Colitis Foundation and Chief Physician of Gastroenterology of the Second Affiliated Hospital of Zhejiang University School of Medicine, China, emphasized: “Shared decision making enables doctors to tailor treatments, helping patients manage their condition and pursue their aspirations — ushering in a new era of dual control. To achieve this, we are enhancing effective patient education in China through digital tools and social media. This allows us to address patient needs by providing a more time- and cost-efficient way to access important information.”

“Building on three decades of commitment to IBD innovation, our goal of this campaign is to bridge care and communication gaps, helping patients not just manage their disease, but reclaim the life and dreams they deserve. When patients are empowered with the right information and actively participate in their care, endoscopic remission becomes more than a possibility—it turns into a meaningful path to dual control,” said Earl Dancel, Vice President of Commercial Strategy at the Asia Pacific Strategy Office, Johnson & Johnson Innovative Medicine Asia Pacific.

The campaign’s educational resources include: a patient empowerment video #MyDualControl: Don’t let IBD put your dreams on hold featuring HCP-patient dialogues, the #YouSeeUC digital program in China to break the myth of remission and promote shared decision making; educational content in Japan with advice from leading healthcare professionals to help IBD patients manage their “Work-Sick Balance”; and patient stories shared via media highlight disease management experiences in Singapore.

###

About the Dual Control Campaign
In collaboration with gastroenterologists, advocacy groups, and the media, the campaign aims to empower patients to take dual control of disease management and life aspirations by striving for endoscopic remission through shared decision-making.

About Inflammatory Bowel Disease
Inflammatory Bowel Disease (IBD) refers to chronic gastrointestinal disorders, including Crohn’s disease and ulcerative colitis[1]. Common symptoms include diarrhea, blood in stool, weight loss, mouth ulcers, and abdominal pain[5]. Since the 21st century, western countries have stabilized IBD incidence rates, while Asia has experienced a continuous rise[3]. Typically beginning in adolescence[4], IBD affects patients schooling[6], careers[7], and relationships[8].

Currently, no cure is available for IBD, and the primary treatment goal is achieving and maintaining remission. IBD remission including symptom control or clinical remission as resolution of active symptoms, mucosal healing (endoscopic remission) refers to an absence of active disease seen during a colonoscopy, and histologic remission (also known as deep remission) occurs when no active inflammation is seen at the tissue level[14].

About Johnson & Johnson
At Johnson & Johnson, we believe health is everything. Our strength in healthcare innovation empowers us to build a world where complex diseases are prevented, treated, and cured, where treatments are smarter and less invasive, and solutions are personal. Through our expertise in Innovative Medicine and MedTech, we are uniquely positioned to innovate across the full spectrum of healthcare solutions today to deliver the breakthroughs of tomorrow and profoundly impact health for humanity.

Learn more at https://www.jnj.com/ or at www.innovativemedicine.jnj.com. Follow us at @JNJInnovMed.

Johnson & Johnson Innovative Medicine Asia Pacific is a division of Johnson & Johnson International (Singapore) Pte. Ltd., which is a Johnson & Johnson company.

© Johnson & Johnson International (Singapore) Pte. Ltd. [2025] All rights reserved.

[1] Crohn’s & Colitis Foundation. (n.d.). What is IBD? Crohn’s & Colitis Foundation. Retrieved September 4, 2025, from https://www.crohnscolitisfoundation.org/patientsandcaregivers/what-is-ibd 

[2] Pathiyil, M. M., Jena, A., Venkataramana Raju, A. K., Omprakash, T. A., Sharma, V., & Sebastian, S. (2023a). Representation and reporting of diverse groups in randomised controlled trials of pharmacological agents in inflammatory bowel disease: A systematic review. The Lancet Gastroenterology & Hepatology, 8(12), 1143–1151. https://doi.org/10.1016/s2468-1253(23)00193-0

[3] Chen, X., Xiang, X., Xia, W., Li, X., Wang, S., Ye, S., Tian, L., Zhao, L., Ai, F., Shen, Z., Nie, K., Deng, M., & Wang, X. (2023). Evolving Trends and Burden of Inflammatory Bowel Disease in Asia, 1990-2019: A Comprehensive Analysis Based on the Global Burden of Disease Study. Journal of epidemiology and global health, 13(4), 725–739. https://doi.org/10.1007/s44197-023-00145-w 

[4] Rosen, M. J., Dhawan, A., & Saeed, S. A. (2015). Inflammatory Bowel Disease in Children and Adolescents. JAMA pediatrics, 169(11), 1053–1060. https://doi.org/10.1001/jamapediatrics.2015.1982 

[5] SingHealth. (n.d.). Inflammatory bowel disease – Conditions & treatments. SingHealth. Retrieved September 4, 2025, from https://www.singhealth.com.sg/symptoms-treatments/inflammatory-bowel-disease 

[6] Giga, A., Pappa, D., Manthou, P., Chryssi, M., Kollia, T., Varvitsioti, D., Giatromanolakis, E., Anastasiou, N., Zigkiri, E., & Mangoulia, P. (2024). Psychological Impact of Inflammatory Bowel Disease on University Students: A Systematic Review. Cureus, 16(4), e59176. https://doi.org/10.7759/cureus.59176 

[7] Marri, S. R., & Buchman, A. L. (2005). The education and employment status of patients with inflammatory bowel diseases. Inflammatory bowel diseases, 11(2), 171–177. https://doi.org/10.1097/00054725-200502000-00011 

[8] Rouncefield-Swales, A., Carter, B., Bray, L., Blake, L., Allen, S., Probert, C., Crook, K., & Qualter, P. (2020). Sustaining, Forming, and Letting Go of Friendships for Young People with Inflammatory Bowel Disease (IBD): A Qualitative Interview-Based Study. International journal of chronic diseases, 2020, 7254972. https://doi.org/10.1155/2020/7254972 

[9] Vermeire, S., Schreiber, S., Petryka, R., Kuehbacher, T., Hebuterne, X., Roblin, X., Klopocka, M., Goldis, A., Wisniewska-Jarosinska, M., Baranovsky, A., Sike, R., Stoyanova, K., Tasset, C., Van der Aa, A., & Harrison, P. (2017). Clinical remission in patients with moderate-to-severe Crohn’s disease treated with filgotinib (the FITZROY study): results from a phase 2, double-blind, randomised, placebo-controlled trial. Lancet (London, England), 389(10066), 266–275. https://doi.org/10.1016/S0140-6736(16)32537-5 

[10] Crohn’s & Colitis Foundation. (2022, December 20). Study finds significant room for improvement in ulcerative colitis treatments. Crohn’s & Colitis Foundation. Retrieved September 4, 2025, from https://www.crohnscolitisfoundation.org/blog/study-finds-significant-room-improvement-ulcerative-colitis-treatments 

[11] Tamura, A., Fujii, T., Chinen, M., Yoshigoe, S., Tsuchiya, H., Matsuoka, K., Okamoto, R., & Hisamatsu, T. (2025, July). Impact on work productivity and its association with fatigue in newly diagnosed patients with Crohn’s disease: A sub-analysis of iCREST-CD [Conference presentation]. 13th Annual Meeting of the Asian Organization for Crohn’s & Colitis (AOCC), Shinjuku-Ku, Tokyo, Japan

[12] Matsuoka, K., Fujii, T., Okamoto, R., et al. (2022). Characteristics of adult patients newly diagnosed with Crohn’s disease: Interim analysis of the nation-wide inception cohort registry study of patients with Crohn’s disease in Japan (iCREST-CD). Journal of Gastroenterology, 57(8), 867–878. https://doi.org/10.1007/s00535-022-01907-2 

[13] Rubin, D. T., Sninsky, C., Siegmund, B., Sans, M., Hart, A., Bressler, B., Bouhnik, Y., Armuzzi, A., & Afzali, A. (2021). International Perspectives on Management of Inflammatory Bowel Disease: Opinion Differences and Similarities Between Patients and Physicians From the IBD GAPPS Survey. Inflammatory bowel diseases, 27(12), 1942–1953. https://doi.org/10.1093/ibd/izab006 

[14] Wood, D. W., Treiman, K., Rivell, A., van Deen, W. K., Heyison, H., Mattar, M. C., Power, S., Strauss, A., Syal, G., Zullow, S., & Ehrlich, O. G. (2025). Communicating Information Regarding IBD Remission to Patients: Evidence From a Survey of Adult Patients in the United States. Inflammatory bowel diseases, 31(6), 1605–1615. https://doi.org/10.1093/ibd/izae201 

[15] Neff-Baro, S., et al. (2024, October 12–15). Endoscopic response at 1-year and association with long-term Crohn’s disease outcome: A pooled clinical trial analysis adjusting for 1-year clinical remission status [Poster presentation, MP153]. United European Gastroenterology Week (UEGW), Vienna, Austria.

[16] Kanazawa, M., Takahashi, F., Tominaga, K., Abe, K., Izawa, N., Fukushi, K., Nagashima, K., Kanamori, A., Takenaka, K., Sugaya, T., Iijima, M., Takada, A., Imai, Y., Hiraishi, H., & Irisawa, A. (2019). Relationship between endoscopic mucosal healing and histologic inflammation during remission maintenance phase in ulcerative colitis: a retrospective study. Endoscopy international open, 7(4), E568–E575. https://doi.org/10.1055/a-0869-7619 

[17] Crohn’s & Colitis Foundation. (n.d.). Treatment approaches: Shared decision-making. Crohn’s & Colitis Foundation. Retrieved September 4, 2025, from https://www.crohnscolitisfoundation.org/patientsandcaregivers/shared-decision-making 

[18] Watanabe, K., Gardiner, S., & Arai, S. (2022). Notable gaps between patients’ and physicians’ perspectives on communication and disease management in Japan: Multifaceted ad hoc analyses of the global Ulcerative Colitis Narrative Survey for further optimal care. Therapeutic Advances in Gastroenterology, 15, 1–12. https://doi.org/10.1177/17562848221095372 

[19] Xu, D., Zhang, H., & Chen, Y. (2021). Patients’ views of shared decision making in inflammatory bowel disease: a survey in China. BMC medical informatics and decision making, 21(1), 340. https://doi.org/10.1186/s12911-021-01702-8 

 

BLUETTI RVSolar 48V Power System Now Available to Streamline Caravans & Boats Installs

By
Advertorial Desk
-

SYDNEY, Sept. 30, 2025 /PRNewswire/ — BLUETTI, a global innovator in clean energy, has released the RVSolar 48V Power System, a fully integrated solution boasting 30-minute core connection for RVs, boats, and off-grid setups. Recently honored with the IFA Innovation Award for “Best in Tech for Good,” the RVSolar is now available on BLUETTI’s website.

BLUETTI RVSolar 48V Power System
BLUETTI RVSolar 48V Power System

Reliable Power That Covers It All
This RVSolar system provides up to 6kW (AC + DC) or 5kVA power, enough to run 99% of RV appliances—from dual-zone air conditioners and water pumps to microwaves and lights. With modular expansion up to 122kWh, it offers extended energy for weekend road trips or months-long boondocking. Its EV-grade LiFePO₄ batteries are IP65-rated water-resistant and feature self-heating, ensuring all-weather power in Australia’s harshest climates.

Screw-and-Go Setup, No Expert Required
At the core is the RV5 Power Hub, a 5-in-1 unit combining an inverter charger, MPPT solar controller, alternator charger, DC converter, and built-in protection. With all wiring included, the streamlined design allows the core system to be set up and powered on in just 30 minutes, up to 90% faster than conventional systems. Automatic self-configuration and miswiring protection add peace of mind for first-time DIYers.

Flexible, Widely Compatible, and DIY-able
The RVSolar recharges in just 90 minutes via campsite hookups, solar, generators, or alternators. Compatible with BLUETTI and third-party parts through CAN, RV-C, and NMEA 2000, it upgrades caravans, motorhomes, yachts, or trailers with ease. Its 48V design is 30% more efficient than 12V systems, while automotive-grade B4810 batteries deliver 6,000+ cycles for up to 17 years. Certified by Intertek, the system ensures safe, reliable, and eco-friendly power.

Smart Control at Your Fingertips
With the optional Epanel Smart Distribution Panel and 10.1-inch Epad screen, travellers can monitor and control up to 4 AC and 20 DC appliances in real time. BLUETTI app offers smarter power management and detailed insights into connected devices, like water tank levels. Built-in AI diagnostics and fault alerts keep users in control, wherever their journey takes them.

Availability and Pricing

The RVSolar 48V Power System officially launched on September 30 on BLUETTI’s official website in Australia. The base package debuts at A$4,799, while the full smart package with Epanel and Epad is available at a launch price of A$5,999. Customers can also enjoy an additional 10% discount by using the code RSS10 at checkout.

CDNetworks Recognized for Strong WAAP Capabilities in IDC China WAAP Vendor Assessment 2025

By
Advertorial Desk
-

SINGAPORE, Sept. 30, 2025 /PRNewswire/ — CDNetworks, the APAC-leading network to deliver edge as a service, has been recognized in the IDC report China WAAP Vendor Technology Capability Assessment, 2025: Collaborative Capabilities of LLM-Firewalls (doc IDC #CHC53140125, August 2025). In the report, CDNetworks received high marks across key dimensions, including Web Application Firewall (WAF), large language model (LLM)-firewall collaboration, API protection and monitoring, and more.

According to IDC, as enterprises increasingly adopt LLMs, Web Application and API Protection (WAAP) solutions must evolve to deliver more advanced defenses. CDNetworks’ proven strengths in LLM-firewall collaboration reinforce its position as a trusted provider of intelligent, comprehensive, and future-ready security protection.

IDC highlights CDNetworks’ strengths in:

  • Closed-Loop Risk Management: Unified lifecycle protection from asset discovery to post-event analysis.
  • Intelligent Real-Time Protection: Multi-engine architecture correlates edge, AI, and big data analysis in real time.
  • Threat Intelligence: Billions of records enriched with feature engineering and risk clustering to enhance accuracy.
  • 24/7 Intelligent Security Operations: LLM-powered monitoring ensures rapid response and incident validation.
  • Global Distributed Architecture: 2,800+ PoPs and 40 scrubbing centers mitigating attacks up to 20 Tbps.
  • Simplified Operations: Unified platform, adaptive policies, and multi-cloud flexibility streamline management.
  • Proven Expertise: Over a decade of security operations across critical industries.

“As the global adoption of LLMs accelerates, securing these models has become an urgent priority,” said Antony Li, APAC Head of Sales at CDNetworks. “IDC’s recognition underscores our strengths in WAAP and intelligent security. We will continue to innovate and collaborate with LLM-firewall to counter AI-powered threats, while safeguarding organizations across industries such as e-commerce and gaming against complex threats, including the OWASP LLM Top 10 and beyond.” 

Download the Report Excerpt

This IDC report also provides forecasts for market and technology trends, along with strategic recommendations for vendors. For detailed analysis, get the full report now.

About CDNetworks

As the APAC-leading network with over 2,800 global PoPs and more than 20 years of technology experience, CDNetworks delivers the fastest and most secure digital experiences to end users. Our diverse products and services include web performance, media delivery, cloud security, zero trust security, and colocation services — all designed to spur business innovation. To learn more, visit cdnetworks.com and follow us on LinkedIn.

First Phosphate Announces $15 Million Private Placement Pursuant to LIFE Offering

By
Advertorial Desk
-
NOT FOR DISTRIBUTION TO UNITED STATES NEWS WIRE SERVICES
OR FOR DISSEMINATION IN THE UNITED STATES

Saguenay, Quebec–(Newsfile Corp. – September 29, 2025) – First Phosphate Corp. (CSE: PHOS) (OTCQX: FRSPF) (FSE: KD0) (“First Phosphate” or the “Company“) is pleased to announce that it has entered into an agreement with Integrity Capital Group Inc. (“Integrity“) to act as lead agent and bookrunner in connection with a “best efforts” private placement (the “Offering“) for the sale of up to 25,000,000 units of the Company (each, a “Unit“) at a price of C$0.60 per Unit (the “Offering Price“) for aggregate gross proceeds of up to $15,000,000.

Each Unit will consist of one common share in the capital of the Company (a “Unit Share“) and one common share purchase warrant of the Company (a “Warrant“). Each Warrant will entitle the holder thereof to acquire one common share in the capital of the Company (a “Warrant Share“) at a price per Warrant Share of C$0.90 for a period of 36 months from the Closing Date (as hereinafter defined). The Company shall make best efforts to obtain the necessary approvals to list the Warrant Shares on the Canadian Securities Exchange (the “CSE“); however, there can be no assurances that it will be successful in obtaining such a listing.

Subject to compliance with applicable regulatory requirements and in accordance with National Instrument 45-106 – Prospectus Exemptions (“NI 45-106“), the Units will be offered for sale to purchasers resident in all jurisdictions of Canada, pursuant to the listed issuer financing exemption under Part 5A of NI 45-106, as amended by Coordinated Blanket Order 45-935 – Exemptions from Certain Conditions of the Listed Issuer Financing Exemption (the “Listed Issuer Financing Exemption“), and may be offered in the United States and offshore jurisdictions on a private placement basis where the Offering can lawfully be made in accordance with applicable laws. The Unit Shares, Warrants and the Warrant Shares, if exercised, will not be subject to a hold period in accordance with applicable Canadian securities legislation if sold to purchasers resident in Canada.

The Company intends to use the net proceeds of the Offering to complete the feasibility study and permitting for the Company’s flagship Bégin-Lamarche Property, for downstream infrastructure development and acquisitions, and for general corporate purposes. The Offering is scheduled to close on October 10, 2025 or such other date or dates as the Company and Integrity may determine (the “Closing Date“).

There is an offering document related to this offering that can be accessed under the issuer’s profile at www.sedarplus.ca and at www.firstphosphate.com. Prospective investors should read this offering document before making an investment decision.

In consideration for their services, the Company has agreed to pay Integrity an aggregate cash commission equal to 8% of gross proceeds of the Offering (subject to reduction to 2.0% on certain president’s list purchases), and to issue that number of non-transferable broker warrants of the Company to Integrity (the “Broker Warrants“) equal to 8.0% of the number of Units sold under the Offering (subject to reduction to 2.0% on certain president’s list purchases). Each Broker Warrant is exercisable to acquire one Common Share at a price of $0.90 per share for a period of 36 months following the Closing Date. The Broker Warrants and Company common shares that will be issuable upon the exercise thereof (if any) will be issued pursuant to available exemptions under NI 45-106 other than the Listed Issuer Financing Exemption and, accordingly, will be subject to a hold period expiring four months and one day following the closing date of the Offering.

The securities have not been and will not be registered under the United States Securities Act of 1933, as amended (the “U.S. Securities Act“) or any state securities laws and may not be offered or sold within the United States or to U.S. Persons unless registered under the U.S. Securities Act and applicable state securities laws or an exemption from such registration is available. This news release does not constitute an offer to sell or a solicitation of an offer to buy nor shall there be any sale of any of the securities in any jurisdiction in which such offer, solicitation or sale would be unlawful.

About First Phosphate Corp.
First Phosphate (CSE: PHOS) (OTCQB: FRSPF) (FSE: KD0) is a mineral development company dedicated to producing high-purity phosphate for the LFP battery industry. The Company is committed to sustainable extraction and purification with a low anticipated carbon footprint. Its vertically integrated model connects phosphate mining directly into the supply chains of North American battery producers. First Phosphate’s flagship project, the Bégin-Lamarche Property in Saguenay-Lac-Saint-Jean, Quebec, contains rare igneous anorthosite rock that yields high-purity phosphate with minimal impurities.

For additional information, please contact:
Bennett Kurtz
Chief Financial Officer
bennett@firstphosphate.com
Tel: +1 (416) 200-0657

Investor Relations: investor@firstphosphate.com
Media Relations: media@firstphosphate.com
Website: www.FirstPhosphate.com

Follow First Phosphate:
X : https://x.com/FirstPhosphate
LinkedIn: https://www.linkedin.com/company/first-phosphate

-30-

Forward-Looking Information and Cautionary Statements
This release includes certain statements that may be deemed “forward-looking information”. Any statement that discusses predictions, expectations, beliefs, plans, projections, objectives, assumptions, future events or performance (often but not always using phrases such as “expects”, or “does not expect”, “is expected”, “anticipates” or “does not anticipate”, “plans”, “budget”, “scheduled”, “forecasts”, “estimates”, “believes” or “intends” or variations of such words and phrases or stating that certain actions, events or results “may” or “could”, “would”, “might” or “will” be taken to occur or be achieved) are not statements of historical fact and may be forward-looking information. In particular, this press release contains forward-looking information relating to, among other things, the completion of the Offering, the anticipated closing date(s) of the Offering, the listing of the Warrants, the intended use of proceeds of the Offering, approval of the CSE and the filing of the Offering Document. Although the Company believes the expectations expressed in such forward-looking statements are based on reasonable assumptions, such statements are not guarantees of future performance and actual results or developments may differ materially from those forward-looking statements. Factors that could cause actual results to differ materially from those in forward-looking statements include market prices, development and exploration successes, and continued availability of capital and financing and general economic, market or business conditions. These statements are based on a number of assumptions including, among other things, assumptions regarding general business and economic conditions; that the Company and other parties will be able to satisfy stock exchange and other regulatory requirements in a timely manner; that CSE approval will be granted in a timely manner subject only to standard conditions and that all conditions precedent to the completion of the Offering will be satisfied in a timely manner. Investors are cautioned that any such statements are not guarantees of future performance and actual results or developments may differ materially from those projected in the forward-looking statements. Accordingly, readers should not place undue reliance on the forward-looking information contained in this press release. The Company does not assume any obligation to update or revise its forward-looking statements, whether because of new information, future events or otherwise, except as required by applicable law. All forward-looking information contained in this release is qualified by these cautionary statements.

The issuer is solely responsible for the content of this announcement.

Etiqa Insurance Singapore Launches Charity Pledge for new Takaful Products

By
Advertorial Desk
-

0.1 percent of first-year regular premium equivalent from Family Takaful products launched after 1 August 2025 will be donated to the Community Chest of Singapore


SINGAPORE – Media OutReach Newswire – 30 September 2025 – Etiqa Insurance Singapore, the insurance arm of Maybank Group, today announced a charity pledge linked to the launch of its latest Takaful products. Invest purpose, a new Shariah-compliant investment-linked plan designed for individuals seeking to align their financial growth with their personal values. It marks the latest addition to Etiqa’s strategic expansion of values-based insurance portfolio, following the successful return of Takaful to the Singapore market in January 2025. This launch comes shortly after Etiqa introduced Invest vista last month, for its financial advisory partners.

Etiqa Launches Charity Pledge for new Takaful Products
Etiqa Launches Charity Pledge for new Takaful Products

As part of this launch, for each policy sold, Etiqa will donate 0.1 percent of proceeds from first-year regular premiums of new Family Takaful products launched after 1 August 2025 to Community Chest.[1] This contribution made by Etiqa, at no additional cost to policyholders without affecting their plan benefits, reflects the company’s commitment to creating positive societal impact and reinforcing the Takaful principle of mutual support and shared responsibility. The amount donated for each policy can fund a week’s pocket money for a primary school student.

Combining Protection with Purpose

Values-based insurance includes coverage that addresses ethical, social, and personal concerns of customers. Benefits often include risk sharing among policyholders, purpose driven plans that combine protection with transparency.

“Today’s consumers are increasingly seeking to align their investments with their personal values — demanding products that deliver not only financial returns, but also a sense of purpose and social responsibility. Etiqa’s Charity Pledge, launched alongside our new Family Takaful portfolio, is designed for Singaporeans who want their investments to be a force for good, where every investment becomes an act of impact for the wider community. By combining the principles of values-based insurance with the act of giving, we are offering a pathway to purposeful wealth creation that resonates with a new generation of conscious investors,” said Raymond Ong, CEO of Etiqa Insurance Singapore.

Launch of Invest purpose

Invest purpose is a Shariah-compliant Investment-linked Plan that combines wealth accumulation with Takaful coverage through a values-based approach; simultaneously addressing the evolving ethical and societal needs of customers.

Key benefits of Invest purpose include:

  • Protection from life’s uncertainties: Takaful coverage for death and terminal illness, with the option to enhance protection through an additional rider.

  • Tailored flexibility for one’s financial journey: Policyholders can choose from premium terms of 10, 15 or 20 years, pause premiums without fees[2], and make two free partial withdrawals from year 4 of their policy.

  • A legacy of purpose: Policyholders can extend the spirit of giving by leaving a lasting legacy. They can nominate beneficiaries for living and/or death benefits or establish a Wakaf (charitable endowment)[3] to support meaningful causes.

To learn more about Invest purpose, please visit: www.etiqa.com.sg/invest-purpose

Invest purpose is underwritten by Etiqa and is a Takaful product certified as Shariah-compliant by Financial Shariah Advisory and Consultancy (FSAC) of Pergas Singapore.

Etiqa Insurance Singapore provides a comprehensive approach to serving the company’s diverse customer base through multi-channel sales. Invest purpose is available through Maybank Singapore while Invest vista is distributed through Etiqa’s own Advisory channel and financial advisory partners from August 2025.

[1] Donation of the amount equivalent to 0.1% of first-year premium received will apply for new regular premium Family Takaful (Life insurance) products launched by Etiqa Insurance Singapore after 1 August 2025. Policies must remain active at the time of the donation to Community Chest.

[2] The Premium-Free Period is a policy feature that allows you to pause regular premium payments without incurring a shortfall charge. Duration of the Premium-Free Period varies by policy year and your chosen premium payment term. Please refer to the policy contract for full details.

[3] Wakaf is an ongoing charity, a voluntary charitable endowment from one’s personal belongings or wealth in the form of cash/property for pious and religious causes.

Hashtag: #EtiqaSingapore #EtiqaSG

The issuer is solely responsible for the content of this announcement.

Etiqa Insurance Pte. Ltd.

Etiqa Insurance Pte. Ltd. (EIPL) is a life and general insurance company licensed and regulated by the Monetary Authority of Singapore and governed by the Insurance Act 1966. Having protected customers in Singapore since 1961 under the name United General Insurance Co. Sdn. Bhd., the company transitioned into the Singapore branch of Etiqa Insurance Berhad in 2009. Today, EIPL in Singapore stands as the pivotal operating entity of Etiqa Insurance Group, a leading insurance and takaful provider in ASEAN.

EIPL offers a comprehensive range of life and general insurance products accessible through its diverse distribution channels, including bancassurance, agents, brokers, financial advisers, partnerships, direct and online sales via Tiq by Etiqa. Etiqa is rated ‘A’ by credit rating agency Fitch for the group’s ‘Favorable’ business profile. EIPL is owned by Maybank Ageas Holdings Berhad, a joint venture combining local market expertise with international insurance knowledge, with 69% ownership by Maybank, the fourth largest banking group in Southeast Asia, and 31% by Ageas, an international insurance group operating across 13 countries.

Maybank Singapore

Maybank is the fourth largest financial institution group in ASEAN by assets. It has been ranked the Best Bank in Asia Pacific and Singapore by The Banker in 2023; and the number one domestic bank in Malaysia for trade finance, according to the Euromoney Trade Finance survey in 2024.

Maybank Singapore is one of the Group’s largest overseas operations and a Qualifying Full Bank in Singapore. As at 31 December 2023, Maybank’s total assets in Singapore were approximately S$80.26 billion. With strategically located banking branches and over 2,000 employees in Singapore, Maybank is well-positioned to provide highly personalised services and locally oriented solutions that will deliver more value to customers.

Flytxt mentioned as a Niche Player for Second Consecutive Year in the 2025 Gartner® Magic Quadrant™ for AI in CSP Customer and Business Operations

By
Advertorial Desk
-

DUBAI, UAE, Sept. 30, 2025 /PRNewswire/ — Flytxt, a leading provider of Enterprise AI for telecom and other subscription businesses, has been named for the second year in a row as a Niche Player in the Gartner Magic Quadrant 2025 for AI in CSP Customer and Business Operations. Flytxt AI is massively trained with trillions of real-world data, and is purpose-built to drive high-impact decisions and actions for CSPs across sales & marketing, product & pricing, and customer care.

Flytxt mentioned in 2025 Gartner® Magic Quadrant™ for second consecutive year
Flytxt mentioned in 2025 Gartner® Magic Quadrant™ for second consecutive year

Flytxt has strengthened its AI solution portfolio with the recent launch of Niya-X, its Agentic AI system that empowers CSPs to take customer engagement to the next level. Niya-X makes engagement more conversational, proactive, context-aware, and autonomous, reducing human intervention while improving the speed and accuracy of actions. It also enables CSPs to adapt strategies, tactical plans, and actions in response to shifts in market dynamics and customer behavior faster compared to generic or custom AI.

“To us, being recognized for the second time in the Gartner Magic Quadrant truly validates our differentiated market play,” said Dr. Vinod Vasudevan, CEO of Flytxt. “CSPs are increasingly operating as digital marketplaces, where speed and efficiency in decision-making directly shape customer and product outcomes. We see strong adoption of Flytxt AI in this new paradigm to drive autonomous decisions and actions that, on one hand, optimize product offerings, and on the other, customer engagement and consumption, accelerating value creation at scale.”

Flytxt has partnered with more than 80 enterprises, including 75 CSPs in over 50 countries, helping them embed AI into everyday decision workflows for driving measurable business outcomes. 

Gartner, Magic Quadrant for AI in CSP Customer and Business Operations, By Pulkit Pandey, Amresh Nandan, Will Rice, Mounish Rai, 26 August 2025

GARTNER is a registered trademark and service mark of Gartner, Inc. and/or its affiliates in the U.S. and internationally, and MAGIC QUADRANT is a registered trademark of Gartner, Inc. and/or its affiliates and are used herein with permission. All rights reserved. Gartner does not endorse any vendor, product or service depicted in its research publications, and does not advise technology users to select only those vendors with the highest ratings or other designation. Gartner research publications consist of the opinions of Gartner’s research organization and should not be construed as statements of fact. Gartner disclaims all warranties, expressed or implied, with respect to this research, including any warranties of merchantability or fitness for a particular purpose.

For more information, please visit : https://flytxt.ai/

 

1...2,4302,4312,432...6,630Page 2,431 of 6,630